Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.49 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | GRM5 | P41594 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | APAF1 | O14727 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2223543 | 0.90 | L3MBTL1 (0.60) | L3MBTL1KMT2AMEN1DDB1CRBN | |
| SCHEMBL27379105 | 0.86 | L3MBTL1 (0.86) | L3MBTL1KMT2AMEN1DDB1CRBN | |
| SCHEMBL180739 | 0.86 | L3MBTL1 (0.86) | L3MBTL1KMT2AMEN1DDB1CRBN | |
| Hydrochloric Acid SCHEMBL6818365 | 0.84 | L3MBTL1 (0.83) | L3MBTL1KMT2AMEN1DDB1CRBN | |
| SCHEMBL5642423 | 0.82 | L3MBTL1 (0.62) | L3MBTL1KMT2AMEN1DDB1CRBN | |
| Bicarbonate SCHEMBL5329298 | 0.81 | L3MBTL1 (0.78) | L3MBTL1KMT2AMEN1DDB1CRBN | |
| SCHEMBL596252 | 0.81 | L3MBTL1 (0.96) | L3MBTL1KMT2AMEN1DDB1CRBN | |
| SCHEMBL158547 | 0.80 | GAA (0.55) | L3MBTL1KMT2AMEN1HRH3POLB | |
| SCHEMBL610772 | 0.79 | L3MBTL1 (1.00) | L3MBTL1KMT2AMEN1DDB1CRBN | |
| SCHEMBL7269112 | 0.79 | L3MBTL1 (1.00) | L3MBTL1KMT2AMEN1DDB1CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6984637-B2 | Cyclic amine derivatives-CCR-3 receptor antagonists | SYNTEX (U.S.A.) LLC (US) | 2006-01-10 | — | — | US | disclosed |
| EP-0903349-B1 | CCR-3 receptor antagonists | HOFFMANN LA ROCHE (CH) | 2006-01-04 | — | — | EP | disclosed |
| US-20040266782-A1 | Cyclic amine derivatives-CCR-3 receptor antagonists | GONG LEYI (US) | 2004-12-30 | — | — | US | disclosed |
| US-6770650-B2 | CHEMOKINE RECEPTOR (CCR) ANTAGONISTS SUCH AS N-(1(S)-(4-(3,4-DICHLOROBENZYL)PIPERAZIN-1-YLMETHYL)-2-METHYLPROPYL)-4 -METHYLBENZAMIDE DIHYDROCHLORIDE SALT FOR TREATMENT OF ASTHMA | SYNTEX (U.S.A.) LLC | 2004-08-03 | — | — | US | disclosed |
| US-6683074-B1 | PYRROLIDINYL, PIPERAZINYL AND AZEPINYL DERIVATIVES; INFLAMMATORY OR ALLERGIC DISEASES | SYNTEX (U.S.A.) LLC | 2004-01-27 | — | — | US | disclosed |
| US-20030153577-A1 | Cyclic amine derivatives-CCR-3 receptor antagonists | ROCHE BIOSCIENCE | 2003-08-14 | — | — | US | disclosed |
| US-6339087-B1 | FOR THERAPY OF INFLAMMATORY OR ALLERGIC DISEASES ARE SELECTED FROM ASTHMA, ALLERGIC RHINITIS, HYPERSENSITIVITY LUNG DISEASES, HYPERSENSITIVITY PNEUMONITIS, EOSINOPHILIC PNEUMONIAS, INFLAMMATORY BOWEL DISEASES, PSORIASIS, DERMATITIS | SYNTEX (U.S.A.) LLC | 2002-01-15 | — | — | US | disclosed |
| US-6323223-B1 | CCR-3 RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, METHODS FOR THEIR USE AND METHODS FOR PREPARING THESE COMPOUNDS. | SYNTEX (U.S.A.) LLC | 2001-11-27 | — | — | US | disclosed |
| EP-0903349-A2 | CCR-3 receptor antagonists | F. HOFFMANN-LA ROCHE AG (CH) | 1999-03-24 | — | — | EP | disclosed |
| US-4663319-A | LIVER DISORDERS | TANABE SEIYSKU CO., LTD. (JP) | 1987-05-05 | — | — | US | disclosed |
| EP-0149534-A2 | Novel thioketene derivatives and process for the preparation thereof | Tanabe Seiyaku Co., Ltd. (JP) | 1985-07-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040266782-A1 | Cyclic amine derivatives-CCR-3 receptor antagonists | CCR3, CCR1, CCRL2 | L3MBTL1 4261/4885KMT2A 2923/4885MEN1 3264/4885 |
| US-20030153577-A1 | Cyclic amine derivatives-CCR-3 receptor antagonists | CCR3, CCR1, CCRL2 | L3MBTL1 4261/4885KMT2A 2923/4885MEN1 3264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.